Researchers showed that PDAC tumor cells present an increased sialylation that could be recognized by Siglec-7 and Siglec-9 on myeloid cells.
6807162 FNJ7WAXN items 1 apa default asc 1
Rodriguez, E., Boelaars, K., Brown, K., Eveline Li, R. J., Kruijssen, L., Bruijns, S. C. M., van Ee, T., Schetters, S. T. T., Crommentuijn, M. H. W., van der Horst, J. C., van Grieken, N. C. T., van Vliet, S. J., Kazemier, G., Giovannetti, E., Garcia-Vallejo, J. J., & van Kooyk, Y. (2021). Sialic acids in pancreatic cancer cells drive tumour-associated macrophage differentiation via the Siglec receptors Siglec-7 and Siglec-9. Nature Communications, 12(1), 1270. https://doi.org/10.1038/s41467-021-21550-4 Cite
Researchers characterized circulating tumor cells for expression of immune checkpoint ligands in men with metastatic prostate cancer as a non-invasive biomarker of immune evasion and immunotherapy benefit.
6445212 7IFZLVQU items 1 apa default asc 1
Zhang, T., Agarwal, A., Almquist, R. G., Runyambo, D., Park, S., Bronson, E., Boominathan, R., Rao, C., Anand, M., Oyekunle, T., Healy, P., McNamara, M. A., Ware, K., Somarelli, J. A., George, D. J., & Armstrong, A. J. (2021). Expression of immune checkpoints on circulating tumor cells in men with metastatic prostate cancer. Biomarker Research, 9(1), 14. https://doi.org/10.1186/s40364-021-00267-y Cite
Scientists revealed previously unidentified insights into the modulation of macrophages to regulate tumor-associated fibrosis, providing a feasible strategy to reverse the immunosuppressive environment and improve the therapeutic outcome of checkpoint immunotherapies.
6630899 9HCZVZGW items 1 apa default asc 1
Scientists detected the levels of both PD-1 and PD-L1 as resistance to iRGD-antiCD3 treatment. Using cord blood-derived T cells, they assessed the activation and effects of iRGD-antiCD3 combined with PD-1 as evidenced by activation markers, Th1/Th2-cytokines, and killing capability against tumor cells in vitro.
[Oncotargets and Therapy]
6445212 3ESKIRIM items 1 apa default asc 1
Zhu, M., Wang, H., Zhou, S., Wei, J., Ding, N., Shao, J., Yu, L., Feng, Z., & Liu, B. (2021, February 5). <p>Combination Therapy with iRGD-antiCD3 and PD-1 Blockade Enhances Antitumor Potency of Cord Blood-Derived T Cells</p>. OncoTargets and Therapy. https://doi.org/10.2147/OTT.S291086 Cite
Researchers demonstrated that IL-21 could be targeted to tumor-reactive T cells by fusion of IL-21 to anti-PD-1 antibody.
6445218 HAGUVMVT items 1 apa default asc 1
Li, Y., Cong, Y., Jia, M., He, Q., Zhong, H., Zhao, Y., Li, H., Yan, M., You, J., Liu, J., Chen, L., Hang, H., & Wang, S. (2021). Targeting IL-21 to tumor-reactive T cells enhances memory T cell responses and anti-PD-1 antibody therapy. Nature Communications, 12(1), 951. https://doi.org/10.1038/s41467-021-21241-0 Cite
China Oncology Focus Limited an affiliate of Lee’s Pharmaceutical Holdings Limited, and Sorrento Therapeutics, Inc. announced that its anti-PD-L1 antibody, socazolimab, licensed from Sorrento to COF for the greater China territory, has been granted breakthrough therapy designation by the China National Medical Products Administration to treat recurrent or metastatic cervical cancer.
[Lee’s Pharmaceutical (Globe Newswire, Inc.)]
6445212 nan items 1 apa default asc 1
Scientists demonstrated that low-dose HDAC inhibitor trichostatin-A markedly reshaped the tumor immune microenvironment by modulating the suppressive activity of infiltrating macrophages and inhibiting the recruitment of myeloid-derived suppressor cells in various tumors.
6445218 3DZK4FQB items 1 apa default asc 1
The authors describe how MSCs can be used to systemically deliver a binary vector containing an oncolytic adenovirus (Ad) together with a helper dependent Ad that expresses IL-12 and checkpoint PD-L1 blocker.
6630899 LMBIT976 items 1 apa default asc 1
Bristol Myers Squibb announced results from the Phase III CheckMate -274 trial, which showed that Opdivo significantly improved disease-free survival as an adjuvant treatment across all randomized patients with surgically resected, high-risk muscle-invasive urothelial carcinoma and in the subgroup of patients whose tumors express PD-L1 ≥1%, meeting both of the study’s primary endpoints.
[Bristol Myers Squibb]
1254621 nan items 1 apa default asc 1
PDS Biotechnology Corporation announced that the National Cancer Institute’s (NCI) Phase II clinical study of PDS0101 for the treatment of advanced human papillomavirus-associated cancers that have progressed or returned after treatment achieved its preliminary objective response.
[PDS Biotechnology Corporation (Globe Newswire, Inc.)]
6445218 nan items 1 apa default asc 1
The up-regulation of laminin γ2 predicted the attenuated efficacy of anti–PD-1 drugs and was associated with unfavorable outcomes in patients with lung cancer or esophageal cancer.
6445218 ASA5XFHM items 1 apa default asc 1
Li, L., Wei, J.-R., Dong, J., Lin, Q.-G., Tang, H., Jia, Y.-X., Tan, W., Chen, Q.-Y., Zeng, T.-T., Xing, S., Qin, Y.-R., Zhu, Y.-H., Li, Y., & Guan, X.-Y. (2021). Laminin γ2–mediating T cell exclusion attenuates response to anti–PD-1 therapy. Science Advances, 7(6), eabc8346. https://doi.org/10.1126/sciadv.abc8346 Cite